Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of “Moderate Buy” by Analysts

Coya Therapeutics, Inc. (NASDAQ:COYA) has earned an average rating of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $16.00.

COYA has been the subject of several research reports. Wall Street Zen lowered shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 23rd. Finally, D. Boral Capital restated a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 16th.

Coya Therapeutics Price Performance

NASDAQ:COYA opened at $3.96 on Tuesday. Coya Therapeutics has a 1 year low of $3.91 and a 1 year high of $7.75. The stock’s 50 day simple moving average is $4.66 and its two-hundred day simple moving average is $5.44. The company has a market cap of $92.89 million, a price-to-earnings ratio of -3.12 and a beta of 0.23.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The firm had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. As a group, analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC lifted its position in Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after buying an additional 13,176 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Coya Therapeutics in the second quarter valued at $119,000. JPMorgan Chase & Co. purchased a new stake in shares of Coya Therapeutics in the third quarter valued at $28,000. CM Management LLC lifted its holdings in shares of Coya Therapeutics by 50.0% in the 3rd quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $1,710,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Dauntless Investment Group LLC lifted its holdings in shares of Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after acquiring an additional 101,932 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.